CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
This study is looking at whether certain medications, called inotropes, help critically ill patients with cardiogenic shock (a serious condition where your heart can't pump enough blood to meet your body's needs). You might receive either dobutamine or milrinone, two common inotrope medications, or a placebo (a treatment with no active medicine, like normal saline). Doctors will closely watch your health and adjust the medication dose as needed. The study wants to see if these medications improve patient outcomes during hospitalization, up to 12 weeks after admission. To join, you must be at least 18 years old and have a specific type of cardiogenic shock. The study is currently recruiting patients, but its overall status is unclear.
- Study design
- This is a multi-center, double-blind, randomized control trial, meaning neither you nor your doctors will know if you're receiving dobutamine, milrinone, or a placebo. The study plans to enroll 346 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your health will be monitored through the duration of your hospitalization, up to 12 weeks following admission.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
At a glance
Conditions
NCT05267886
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Hamilton Health Sciences
Hamilton, Ontario, Canadastudy coordinator listed
Recruiting
Mayo Clinic
Rochester, Minnesotastudy coordinator listed
Not yet recruiting
University of Ottawa Heart Institute
Ottawa, Ontario, Canadastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Rebecca Mathew, MD · PRINCIPAL_INVESTIGATOR · Ottawa Heart Institute Research Corporation
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Primary composite outcomeThrough duration of hospitalization, up to 12 weeks following admission
The primary outcome will be a composite of: 1. All-cause mortality during the hospitalization 2. Measured within the first 12 hours of starting the study intervention, any of: 1. Sustained hypotension (mean arterial pressure ≤55mmHg) or sustained requirement of high dose vasopressors (norepinephrine \>0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for \>/= 60 minutes 2. Lactate greater than 3.5 mmol/L at 6 hours or thereafter 3. Need for mechanical circulatory support device 4. Atrial or ventricular arrhythmia leading to emergent electrical cardioversion 5. Resuscitated cardiac arrest